Analysis on the positive rate of M2 anti-mitochondrial antibodies in physical examine screening in Shanghai

doi:10.3969/j.issn.1673-8640.2015.03.002

Abstract

Abstract: Objective

To investigate the early screening significance of M2 anti-mitochondrial antibodies(AMA-M2) for primary biliary cirrhosis(PBC) in physical examine, through analyzing the positive rate of AMA-M2.

Methods

Serum samples were collected from 6 658 healthy subjects(3 845 males and 2 813 females), and the sex ratio was 1.37∶1. Their age was 46±13. AMA-M2 was quantitatively determined by enzyme-linked immunosorbent assay(ELISA). Serum alanine aminotransferase(ALT), aspartate aminotransferase(AST), alkaline phosphatase(ALP) and gamma glutamyltransferase (GGT) were determined, and the results were analyzed cemparatively.

Results

AMA-M2 were detected in 97 of 6 658 healthy subjects(1.46%), including 44 males (1.14%) and 53 females(1.88%), and the sex ratio was 1∶1.2. AMA-M2 positive rate of females above 46 years old was higher than those below 46 years old (P<0.01). The 8 of 97 AMA-M2 positive cases without PBC clinical feature had increasing ALP and GGT.

Conclusions

Physical examination should pay attention to the correlation analysis of AMA-M2 with ALP/GGT and ALT with AST. AMA-M2 screening is an effective mean to high risk population in the early detection of PBC. According to American Association for the Study of Liver Disease (AASLD) PBC liver disease diagnostic criteria, positive AMA-M2 and serum liver enzyme help with improving the early detection rate of PBC.

Key words: M2 anti-mitochondrial antibody, Primary biliary cirrhosis, Physical examination, Positive rate, Autoimmunity disease

CLC Number:

R446.1

CAI Yiting, HUANG Sheng, XIE Songye. Analysis on the positive rate of M2 anti-mitochondrial antibodies in physical examine screening in Shanghai[J]. Laboratory Medicine, 2015, 30(3): 214-218.

Figures/Tables 3

References 15

[1]	SELMI C, BOWLUS CL, GERSHWIN ME, et al. Primary biliary cirrhosis[J]. Lancet, 2011, 377(9777): 1600-1609.
[2]	姜小华, 仲人前, 孔宪涛, 等. 原发性胆汁性肝硬化发病机制研究进展[J]. 中国免疫学杂志, 2002, 18(8): 586-589.
[3]	METCALF JV, MITCHISON HC, PALMER JM, et al. Natural history of early primary biliary cirrhosis[J]. Lancet, 1996, 348(9039): 1399-1402.
[4]	LINDOR KD, GERSHWIN ME, POUON R, et al. Primary biliary cirrhosis[J]. Hepatology, 2009, 50: 291-308.
[5]	杨国香, 李丽君, 董小娟, 等. 抗线粒体抗体阳性患者的AMA-M2亚型检测及ANA核型分析[J]. 国际检验医学杂志, 2010, 31(1): 39-41.
[6]	KIM WR, LINDOR KD, LOCKE GR 3RD, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community[J]. Gastroenterology, 2000,119(6):1631-1636.
[7]	SOOD S, GOW PJ, CHRISTIE JM, et al. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations[J]. Gastroenterology, 2004,127(2):470-475.
[8]	PRINCE MI, JAMES OF. The epidemiology of primary biliary cirrhosis[J]. Clin Liver Dis, 2003,7(4):795-819.
[9]	JAMES OF, BHOPAL R, HOWEL D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom[J]. Hepatology, 1999,30(2):390-394.
[10]	LIU H, LIU Y, WANG L, et al.Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China[J]. BMC Gastroenterol, 2010,10:100.
[11]	SHIBATA M, ONOZUKA Y, MORIZANE T, et al.Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture[J]. J Gastroenterol, 2004,39(3):255-259.
[12]	MATTALIA A, QUARANTA S, LEUNG PS, et al.Characterization of antimitochondrial antibodies in healthy adults[J]. Hepatology, 1998,27(3):656-661.
[13]	李晓良, 杨大国, 林巧, 等. 1 335例慢性乙肝肝炎患者血清自身抗体检测分析[J]. 中西医结合肝病杂志, 2006,16(3):162-163.
[14]	杨建轩, 闫惠平, 檀玉芬, 等.药物性肝损伤患者的自身抗体分析[J]. 临床荟萃, 2008,23(14):992-995.
[15]	MOURITSEN S, DEMANT E, PERMIN H, et al.High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases[J]. Clin Exp Immunol, 1986,66(1):68-76.

年龄(岁)	例数	男性		女性		阳性数合计(%)
年龄(岁)	例数	例数	阳性数(%)	例数	阳性数(%)	阳性数合计(%)
16~45	3 203	1 746	20(1.15)	1 457	17(1.17)	37(1.16)
46~55	1 769	1 028	10(0.97)	741	16(2.16)	26(1.46)
56~65	1 316	852	11(1.29)	464	14(3.02)	25(1.90)
66~75	273	168	3(1.78)	105	4(3.81)	7(2.57)
>75	97	51	0(0.00)	46	2(4.35)	2(2.06)
合计	6 658	3 845	44(1.14)	2 813	53(1.88)	97(1.46)

年龄(岁)	例数	男性		女性		阳性数合计(%)
年龄(岁)	例数	例数	阳性数(%)	例数	阳性数(%)	阳性数合计(%)
16~45	3 203	1 746	20(1.15)	1 457	17(1.17)	37(1.16)
46~55	1 769	1 028	10(0.97)	741	16(2.16)	26(1.46)
56~65	1 316	852	11(1.29)	464	14(3.02)	25(1.90)
66~75	273	168	3(1.78)	105	4(3.81)	7(2.57)
>75	97	51	0(0.00)	46	2(4.35)	2(2.06)
合计	6 658	3 845	44(1.14)	2 813	53(1.88)	97(1.46)

受检者	性别	年龄(岁)	AMA-M2(RU/mL)	ALP(IU/L)	GGT(IU/L)	ALT(IU/L)	AST(IU/L)
1	女	58	>800	515	436	44	106
2	女	41	>800	132	155	27	35
3	女	66	608	150	119	15	24
4	女	54	608	215	491	51	70
5	女	50	161	453	465	28	62
6	女	79	158	186	192	15	33
7	女	75	50	247	144	65	81
8	男	42	38	240	105	111	302

受检者	性别	年龄(岁)	AMA-M2(RU/mL)	ALP(IU/L)	GGT(IU/L)	ALT(IU/L)	AST(IU/L)
1	女	58	>800	515	436	44	106
2	女	41	>800	132	155	27	35
3	女	66	608	150	119	15	24
4	女	54	608	215	491	51	70
5	女	50	161	453	465	28	62
6	女	79	158	186	192	15	33
7	女	75	50	247	144	65	81
8	男	42	38	240	105	111	302

组别	例数	ALP		GGT		ALT		AST
组别	例数	浓度 (IU/L)	阳性数 (%)	浓度 (IU/L)	阳性数 (%)	浓度 (IU/L)	阳性数 (%)	浓度 (IU/L)	阳性数 (%)
AMA-M2低浓度组	62	55.0 (45.0,71.5)	2 (3.22)	22.0 (15.0,41.0)	12 (19.35)	10.0 (7.0,16.8)	2 (3.22)	18.0 (15.0,24.0)	2 (3.22)
AMA-M2高浓度组	35	77.0 (56.0,122.0)	6 (17.14)	52.0 (22.0,139.0)	18 (51.43)	15.0 (12.0,27.0)	6 (17.14)	24.0 (19.0,31.2)	6 (17.14)